Jordyn Sava is an editor for Targeted Oncology.
Lenvatinib Gets Updated Label to Include First-Line Efficacy in Advanced nccRCC
August 20th 2024The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
August 19th 2024The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
August 16th 2024The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.
AUGMENT-101 Trial of Revumenib Meets Primary End Point in KMT2Ar Acute Leukemia
August 12th 2024The AUGMENT-101 trial demonstrated that revumenib achieved a 23% complete remission rate in patients with relapsed/refractory KMT2A-rearranged acute leukemia, with a well-tolerated safety profile and durable responses.
AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer
August 9th 2024The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.
FDA Clears SeCore CDx as Companion Diagnostic for Afami-cel in Synovial Sarcoma
August 7th 2024The FDA has granted 510(k) clearance to the SeCore™ CDx HLA A sequencing system as companion diagnostic for afamitresgene autoleucel in synovial sarcoma, paving the way for a first-of-its-kind solid tumor therapy.